FDA Approves Treosulfan with Fludarabine As a Preparative Regimen for alloHSCT in Adult and Paediatric Patients with AML or MDS By Ogkologos - March 13, 2025 943 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MC-FludT.14/L Trial II Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR ESMO Immuno-Oncology Congress 2023, 6-8 December 2023, Geneva, Switzerland November 29, 2023 PD1 and LAG3 Inhibition Plus Chemoradiotherapy in the Neoadjuvant Setting for... March 28, 2024 Treatment Strategy for ecDNA-Driven Tumors Shows Potential December 5, 2024 Commemorating and Making History: The National Cancer Act 50th Anniversary February 8, 2021 Load more HOT NEWS Survival Benefit of Enfortumab Vedotin and Pembrolizumab Compared with Chemotherapy in... EMA Recommends Granting a Marketing Authorisation for Retifanlimab Five Questions With…Francisco. FDA Approves Daratumumab and Hyaluronidase-fihj with Bortezomib, Lenalidomide, and Dexamethasone for...
